Genetic testing that is priced $400 to $4,000 is not accessible to all Americans unless covered under insurance. Half of the women who are carrying the two gene mutation which causes breast and ovaries cancer do not qualify for the test under the insurance cover.
Color genomics is made up of former Google and twitter developers. The company is hoping to cut the cost of the genetic testing for breast and ovarian cancer risk.
The company is providing genetic testing for $249, and hence making it available to very women.
Color offers the comprehensive testing with a spit kit which is ordered online and sent to recipients by mail. After the kits are returned, Color will analyze 19 genes including the BRCA1 and BRCA2, the two genes mutations which are linked to breast and ovarian cancer.
After the result of the test is received, testers will be able to get in touch with the board certified genetic counselors at Color about the next steps based on the results and screening prevention plan.
Color’s CEO and cofounder Elad Gil said, the company has taken existing testing process and optimized every step and “There are a lot of pieces that can be automated.”
Color is a laboratory developed test that is run in color’s laboratory under the federal regulatory standards that apply to all clinical laboratory testing.
Like other physician ordered genetic test for BRCA1 and BRCA2, Color is one of them.
The customers need to have their own physician request for the test or the Color’s physician should approve a request for the test.
Color is collaborating with the healthcare providers at University of California and University of Pennsylvania. Genetic experts are also collaborating with the company like Dr. Mary-Claire King, who discovered BRCA1 gene.
Color is also launching the “Every Woman Program” which works with cancer centers to provide genetic tests for patients who cannot afford it.